Biotech Specialty Pharma

Peregrine Pharmaceuticals

14282 Franklin Avenue
Tustin, CA 92780 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Peregrine is a biopharmaceutical company developing novel monoclonal antibody drugs for cancer and serious viral infections.

Management Steven W. King, President and CEO, Director; Paul J. Lytle, CPA, Chief Financial Officer; Robert Garnick, Ph.D., Head of Regulatory Affairs; Marvin R. Garovoy, MD, Head of Clinical Science; Joseph Shan, M.P.H., Vice President, Clinical & Regulatory Affairs

Click here for Financial Data
Keywords: oncology, pharmaceutical, peregrine, monoclonal, bavituximab

Comment


Updated: Dec. 10, 2013


Description

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections.......view more

Products / Services

Peregrine has an extensive pipeline of platform technologies which are in various stages of pre-clinical and clinical development. The companys current philosophy is to conduct basic research and ear......view more

Technology / Differentiation

Phosphatidylserine (PS)-Targeting Technology Platform Bavituximab is the first in a new class of targeted anti-phosphatidylserine (PS) antibodies that targets and binds to the cellular membrane compon...view more

Market / Customers

Peregrine's lead products bavituximab and Cotara are in mid-stage development for solid cancers, the second leading cause of death worldwide. In view of bavituximab's unique target, we expect that it ......view more


Competitors / Substitutes / Alternatives

Other marketed cancer drugs and drugs in development, and other anti-viral therapies in development. Major unmet needs for improved therapies remain....view more

Status

Peregrine is committed to commercializing at least one product in the next 2.5-5 years. It plans to initiate a definitive bavituximab NSCLC Phase II clinical trial in early 2010 and is assessing optio...view more

RELATED COMPANIES



0000-00-00-6966